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Since the emergence of Middle East respiratory syndrome coro-navirus (MERS-CoV) on the Arabian Peninsula in 2012, there MyD88 signaling was largely repressed by the use of statins inMERS patients, this could lead to exacerbated compensatory sig-
naling by other innate immune factors, resulting in a poor disease
outcome in coronavirus patients. Of critical importance is that the
absence of these central TLR adaptor molecules results in in-
creased viral loads that persist for longer periods of time than in
wild-type mice following SARS-CoV or MERS-CoV infection (7,
13, 14). Currently, high viral titers during the acute phase of in-
fection are thought to be a potential factor that increases the like-
lihood of person-to-person transmission of highly pathogenic
coronaviruses. Caution must be used when weighing potential
therapeutic options that may increase the likelihood of the spread
of these viruses.
Immunomodulatory drugs have great appeal as potential an-
tiviral medications, due to the promise of broad-spectrum thera-
peutics that may be suitable against a number of different patho-
gens or maladies, depending on the downstream inflammatory
gene expression profile. However, while there is a great need for
treatment options for highly pathogenic coronaviruses that are
already known to be safe in humans, we must temper our hope for
these drugs against the potential of these immunomodulatory
agents to cause more severe disease or increased transmission in
MERS patients. Reliance on data from cell culture experiments is
not likely to yield helpful assessments of drug efficacy against
highly pathogenic coronaviruses, as ribavirin and interferon are
both highly effective against coronavirus infection in vitro but not
in human patients (5, 6). The recent development of small-animal
models of MERS-CoV infection offers a viable platform to test
larger numbers of antiviral therapeutics and will be of critical im-
portance in the development of medical countermeasure strate-
gies against MERS or other emergent highly pathogenic corona-
viruses (14, 15). As we now know, the ongoing MERS-CoV
outbreak in the Middle East has the potential to spread elsewhere,
indicating that there is a critical need for basic research on highly
pathogenic coronaviruses and that applied studies on potential
therapeutic options could make significant contributions to
global public health.
REFERENCES
1. World Health Organization. 29 July 2015. Middle East Respiratory Syn-
drome coronavirus (MERS-CoV)—Saudi Arabia. World Health Organi-
zation, Geneva, Switzerland. http://www.who.int/csr/don/29-july-2015-
mers-saudi-arabia/en/.
2. Korea Centers for Disease Control and Prevention. 28 July 2015. Central
MERS-CoV Control Office: MERS statistics. Ministry of Health & Wel-
Published 29 September 2015
Citation Totura AL, Baric RS. 2015. Reply to “Statins may decrease the fatality rate of
MERS infection.” mBio 6(5):e01303-15. doi:10.1128/mBio.01303-15.
Copyright © 2015 Totura and Baric. This is an open-access article distributed under the
terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported
license, which permits unrestricted noncommercial use, distribution, and reproduction
in any medium, provided the original author and source are credited.
Address correspondence to Ralph S. Baric, rbaric@email.unc.edu.
has been a steady stream of MERS cases geographically focused in 
the Middle East, indicating that either zoonotic transmission from 
camel to human or person-to-person transmission likely takes 
place on a frequent basis (1). As reaffirmed by the recent MERS 
outbreak in South Korea, highly pathogenic coronaviruses are ca-
pable of causing epidemics affecting hundreds of individuals as a 
result of sustained person-to-person transmission in nosocomial 
settings that can be linked to a single traveler who became an index 
patient (2). Currently, the best public health strategy to circum-
vent sustained coronavirus transmission in an outbreak situation 
is to quarantine individuals who have a history of contact with 
confirmed cases of MERS. In the most recent outbreak in South 
Korea, this led to the isolation and monitoring of more than 
16,000 individuals, a feat that may not be economically or logisti-
cally feasible in future outbreaks (2). Due to the diversity and 
presence of prepandemic zoonotic coronaviruses in bat popula-
tions, we may expect the continual reemergence of highly patho-
genic coronaviruses related to MERS-CoV, SARS-CoV (severe 
acute respiratory syndrome coronavirus), or other CoV strains to 
be a future risk to global public health (3, 4). There is clearly a need 
for coronavirus-specific medical countermeasure strategies 
against these respiratory pathogens, as studies indicate that gen-
eral antiviral medications like interferon and ribavirin are ineffec-
tive in MERS or SARS patients (5, 6).
Yuan suggests in a comment on our recent paper (7, 8) that 
immunomodulatory therapeutic administration of an early, high 
dose of statins to treat acute MERS or SARS patients should be an 
experimental course of treatment. The author anticipates that 
treatment with statins would inhibit MyD88 signaling and down-
stream NF-B responses, predicting an inhibition of inflamma-
tory responses that would lead to improved disease outcomes in 
MERS patients. Although there is a linkage in MERS and SARS 
patient samples between aberrant signaling of interferon-
stimulated genes or cytokines and severe coronavirus-induced 
disease, innate immune signaling is still required for an effective 
immune response that results in less severe disease following coro-
navirus infection (9, 10). While testing drugs like statins that are 
already know to be safe for human use is an attractive concept, 
there is no evidence that the combination of attenuated MyD88 
and NF-B signaling would improve disease outcome compared 
to the outcome using NF-B-inhibiting drugs, which do increase 
survival in mouse models of SARS-CoV infection (11). Impor-
tantly, the efficacy of NF-B inhibitors, statins, or other therapeu-
tics should be rigorously evaluated in more vulnerable aged-
mouse models which replicate the increased severity of 
coronavirus disease seen in elderly humans (12).
Our study and others indicate that, in animal models of highly 
pathogenic coronavirus infection, the aberrant signaling stem-
ming from a lack of either Toll-like receptor (TLR) adaptor TRIF 
or MyD88 leads to severe lung disease or death (7, 13, 14). If
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